Katherine L. Ruffner

Cardiff Oncology Inc (NASDAQ: CRDF) shares are trading lower after the company announced data from its lead clinical program evaluating onvansertib in combination with standard-of-care FOLFIRI/bevacizumab. "As we have increased the number of patients evaluated and the duration of follow-up,...